BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Regulation of post-translational modification in breast cancer treatment

  • Heo, Kyung-Sun (College of Pharmacy and Institute of Drug Research and Development, Chungnam National University)
  • Received : 2018.11.01
  • Published : 2019.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The small ubiquitin-related modification molecule (SUMO), one of the post-translational modification molecules, is involved in a variety of cellular functions where it regulates protein activity and stability, transcription, and cell cycling. Modulation of protein SUMOylation or deSUMOylation modification has been associated with regulation of carcinogenesis in breast cancer. In the dynamic processes of SUMOylation and deSUMOylation in a variety of cancers, SUMO proteases (SENPs), reverse SUMOylation by isopeptidase activity and SENPs are mostly elevated, and are related to poor patient prognosis. Although underlying mechanisms have been suggested for how SENPs participate in breast cancer tumorigenesis, such as through regulation of target protein transactivation, cancer cell survival, cell cycle, or other post-translational modification-related machinery recruitment, the effect of SENP isoform-specific inhibitors on the progression of breast cancer have not been well evaluated. This review will introduce the functions of SENP1 and SENP2 and the underlying signaling pathways in breast cancer for use in discovery of new biomarkers for diagnosis or therapeutic targets for treatment.

Keywords

References

  1. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-10874 https://doi.org/10.1073/pnas.191367098
  2. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502 https://doi.org/10.1001/jama.295.21.2492
  3. Mander S, You DJ, Park S et al (2018) Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells. Arch Pharm Res 41, 229-242 https://doi.org/10.1007/s12272-017-0996-9
  4. Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15, 2302-2310 https://doi.org/10.1158/1078-0432.CCR-08-2132
  5. Pearce ST and Jordan VC (2004) The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50, 3-22 https://doi.org/10.1016/j.critrevonc.2003.09.003
  6. Chen GG, Zeng Q and Tse GM (2008) Estrogen and its receptors in cancer. Med Res Rev 28, 954-974 https://doi.org/10.1002/med.20131
  7. Chen J, Kinyamu HK and Archer TK (2006) Changes in attitude, changes in latitude: nuclear receptors remodeling chromatin to regulate transcription. Mol Endocrinol 20, 1-13 https://doi.org/10.1210/me.2005-0192
  8. Lonard DM and O'Malley BW (2007) Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 27, 691-700 https://doi.org/10.1016/j.molcel.2007.08.012
  9. Peterson TJ, Karmakar S, Pace MC, Gao T and Smith CL (2007) The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 27, 5933-5948 https://doi.org/10.1128/MCB.00237-07
  10. Privalsky ML (2004) The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66, 315-360 https://doi.org/10.1146/annurev.physiol.66.032802.155556
  11. Green AR, Burney C, Granger CJ et al (2008) The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 110, 427-437 https://doi.org/10.1007/s10549-007-9737-y
  12. Smith CL, Migliaccio I, Chaubal V et al (2012) Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat 136, 253-265 https://doi.org/10.1007/s10549-012-2262-7
  13. Blackmore JK, Karmakar S, Gu G et al (2014) The SMRT coregulator enhances growth of estrogen receptor-alphapositive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis. Endocrinology 155, 3251-3261 https://doi.org/10.1210/en.2014-1002
  14. Planas-Silva MD, Shang Y, Donaher JL, Brown M and Weinberg RA (2001) AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res 61, 3858-3862
  15. Ishii S, Kurasawa Y, Wong J and Yu-Lee LY (2008) Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A 105, 4179-4184 https://doi.org/10.1073/pnas.0710140105
  16. Lim J, Song Y, Jang JH et al (2018) Aspirin-inspired acetyl-donating HDACs inhibitors. Arch Pharm Res 41, 967-976 https://doi.org/10.1007/s12272-018-1045-z
  17. Heo KS, Chang E, Le NT et al (2013) De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res 112, 911-923 https://doi.org/10.1161/CIRCRESAHA.111.300179
  18. Melchior F (2000) SUMO--nonclassical ubiquitin. Annu Rev Cell Dev Biol 16, 591-626 https://doi.org/10.1146/annurev.cellbio.16.1.591
  19. Qin Y, Bao H, Pan Y et al (2014) SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma. Mol Med Rep 9, 877-881 https://doi.org/10.3892/mmr.2014.1882
  20. Heo KS, Lee H, Nigro P et al (2011) PKCzeta mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol 193, 867-884 https://doi.org/10.1083/jcb.201010051
  21. Heo KS, Berk BC and Abe J (2016) Disturbed flow-induced endothelial proatherogenic signaling via regulating posttranslational modifications and epigenetic events. Antioxid Redox Signal 25, 435-450 https://doi.org/10.1089/ars.2015.6556
  22. Deyrieux AF and Wilson VG (2017) Sumoylation in development and differentiation. Adv Exp Med Biol 963, 197-214 https://doi.org/10.1007/978-3-319-50044-7_12
  23. Heo KS, Chang E, Takei Y et al (2013) Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arterioscler Thromb Vasc Biol 33, 321-329 https://doi.org/10.1161/ATVBAHA.112.300619
  24. Bialik P and Wozniak K (2017) SUMO proteases as potential targets for cancer therapy. Postepy Hig Med Dosw (Online) 71, 997-1004
  25. Mukhopadhyay D, Ayaydin F, Kolli N et al (2006) SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J Cell Biol 174, 939-949 https://doi.org/10.1083/jcb.200510103
  26. Gong L, Ji WK, Hu XH et al (2014) Sumoylation differentially regulates Sp1 to control cell differentiation. Proc Natl Acad Sci U S A 111, 5574-5579 https://doi.org/10.1073/pnas.1315034111
  27. Wang CM, Brennan VC, Gutierrez NM, Wang X, Wang L and Yang WH (2013) SUMOylation of ATF3 alters its transcriptional activity on regulation of TP53 gene. J Cell Biochem 114, 589-598 https://doi.org/10.1002/jcb.24396
  28. Jacques C, Baris O, Prunier-Mirebeau D et al (2005) Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90, 2314-2320 https://doi.org/10.1210/jc.2004-1337
  29. Cheng J, Bawa T, Lee P, Gong L and Yeh ET (2006) Role of desumoylation in the development of prostate cancer. Neoplasia 8, 667-676 https://doi.org/10.1593/neo.06445
  30. Chiu SY, Asai N, Costantini F and Hsu W (2008) SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol 6, e310 https://doi.org/10.1371/journal.pbio.0060310
  31. Abdel-Hafiz HA and Horwitz KB (2012) Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol 13, 10-18 https://doi.org/10.1186/1471-2199-13-10
  32. Nait Achour T, Sentis S, Teyssier C et al (2014) Transcriptional repression of estrogen receptor alpha signaling by SENP2 in breast cancer cells. Mol Endocrinol 28, 183-196 https://doi.org/10.1210/me.2013-1376
  33. Liou YC, Zhou XZ and Lu KP (2011) Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 36, 501-514 https://doi.org/10.1016/j.tibs.2011.07.001
  34. Lu KP and Zhou XZ (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8, 904-916 https://doi.org/10.1038/nrm2261
  35. Min SH, Zhou XZ and Lu KP (2016) The role of Pin1 in the development and treatment of cancer. Arch Pharm Res 39, 1609-1620 https://doi.org/10.1007/s12272-016-0821-x
  36. Yuan WC, Lee YR, Huang SF et al (2011) A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 20, 214-228 https://doi.org/10.1016/j.ccr.2011.07.008
  37. Girardini JE, Napoli M, Piazza S et al (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20, 79-91 https://doi.org/10.1016/j.ccr.2011.06.004
  38. Cheng J, Kang X, Zhang S and Yeh ET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131, 584-595 https://doi.org/10.1016/j.cell.2007.08.045
  39. Chen CH, Chang CC, Lee TH et al (2013) SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. Cancer Res 73, 3951-3962 https://doi.org/10.1158/0008-5472.CAN-12-4360
  40. Giacinti L, Claudio PP, Lopez M and Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11, 1-8
  41. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61, 7025-7029
  42. Lee JY, Won HY, Park JH et al (2015) MEL-18 loss mediates estrogen receptor-alpha downregulation and hormone independence. J Clin Invest 125, 1801-1814 https://doi.org/10.1172/JCI73743
  43. Ishida A, Asano H, Hasegawa M et al (1993) Cloning and chromosome mapping of the human Mel-18 gene which encodes a DNA-binding protein with a new 'RING-finger' motif. Gene 129, 249-255 https://doi.org/10.1016/0378-1119(93)90275-8
  44. Sauvageau M and Sauvageau G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313 https://doi.org/10.1016/j.stem.2010.08.002
  45. Won HY, Lee JY, Shin DH et al (2012) Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. FASEB J 26, 5002-5013 https://doi.org/10.1096/fj.12-209247
  46. Lee JY, Park MK, Park JH et al (2014) Loss of the polycomb protein Mel-18 enhances the epithelialmesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 33, 1325-1335 https://doi.org/10.1038/onc.2013.53
  47. Fu M, Wang C, Zhang X and Pestell R (2003) Nuclear receptor modifications and endocrine cell proliferation. J Steroid Biochem Mol Biol 85, 133-138 https://doi.org/10.1016/S0960-0760(03)00223-1
  48. Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A and Milgrom E (2003) Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278, 12335-12343 https://doi.org/10.1074/jbc.M207148200
  49. Sentis S, Le Romancer M, Bianchin C, Rostan MC and Corbo L (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19, 2671-2684 https://doi.org/10.1210/me.2005-0042
  50. Liu XF and Bagchi MK (2004) Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 279, 15050-15058 https://doi.org/10.1074/jbc.M311932200
  51. Suzuki A, Sanda N, Miyawaki Y et al (2010) Downregulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem 285, 13444-13453 https://doi.org/10.1074/jbc.M109.062430
  52. Qiao Z, Wang W, Wang L et al (2011) Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorg Med Chem Lett 21, 6389-6392 https://doi.org/10.1016/j.bmcl.2011.08.101
  53. Madu IG, Namanja AT, Su Y, Wong S, Li YJ and Chen Y (2013) Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol 8, 1435-1441 https://doi.org/10.1021/cb400177q
  54. Albrow VE, Ponder EL, Fasci D et al (2011) Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. Chem Biol 18, 722-732 https://doi.org/10.1016/j.chembiol.2011.05.008
  55. Uno M, Koma Y, Ban HS and Nakamura H (2012) Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors. Bioorg Med Chem Lett 22, 5169-5173 https://doi.org/10.1016/j.bmcl.2012.06.084
  56. Kumar A, Ito A, Takemoto M, Yoshida M and Zhang KY (2014) Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening. J Chem Inf Model 54, 870-880 https://doi.org/10.1021/ci4007134
  57. Huang W, He T, Chai C et al (2012) Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One 7, e37693 https://doi.org/10.1371/journal.pone.0037693
  58. Wu J, Lei H, Zhang J et al (2016) Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget 7, 58995-59005 https://doi.org/10.18632/oncotarget.10636
  59. Ma C, Wu B, Huang X et al (2014) SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9. Tumour Biol 35, 12729-12735 https://doi.org/10.1007/s13277-014-2598-1
  60. Shen HJ, Zhu HY, Yang C and Ji F (2012) SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev 13, 3583-3587 https://doi.org/10.7314/APJCP.2012.13.8.3583
  61. Tan M, Gong H, Wang J et al (2015) SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1. Sci Rep 5, 13996-14004 https://doi.org/10.1038/srep13996
  62. Tan M, Zhang D, Zhang E et al (2017) SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-betaRI. Mol Carcinog 56, 2332-2341 https://doi.org/10.1002/mc.22687
  63. Hu XY, Liu Z, Zhang KL et al (2017) SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells. Cancer Biomark 21, 195-201 https://doi.org/10.3233/CBM-170651
  64. Chang CC, Huang YS, Lin YM et al (2018) The role of sentrin-specific protease 2 substrate recognition in TGF-beta-induced tumorigenesis. Sci Rep 8, 9786-9798 https://doi.org/10.1038/s41598-018-28103-8
  65. Wang CM, Liu R, Wang L, Nascimento L, Brennan VC and Yang WH (2014) SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells. Int J Mol Sci 15, 10233-10251 https://doi.org/10.3390/ijms150610233